Retatrutide: evidence now greater than just weight loss
Emerging research: a 2026 combined analysis of randomized trials shows retatrutide moves blood pressure and cholesterol numbers — not just weight. Still not approved.
Member Dashboard
Welcome back.
Your physician-curated research platform is ready.
Educational only
Vanguard Optimization provides physician-led education, not medical advice. The AI assistant, supplement stack tracker, and monograph library are research tools — not a substitute for licensed clinical care. For anything involving your personal labs, dosing, symptoms, interactions, or whether content here applies to your situation, consult your clinician. We do not prescribe, diagnose, or establish doctor-patient relationships through this platform.
The Proven Supplements Starter Guide
The short list that survives the evidence — every supplement graded, and updated as new compounds earn their place. Included with your membership.
V
Vanguard AI ● Online
Ask the Research Assistant
Evidence-based answers on supplements, hormonal health, peptides, longevity protocols, and metabolic optimization — available 24/7.
Learning Paths
Physician-sequenced routes through the library — foundational to advanced, one topic at a time.
Monograph Library
Browse physician-reviewed research by topic.
Latest Research
Recently published protocols and summaries.
N-Acetylcysteine: the antidote is real, the capsule claims are not
N-acetylcysteine is an FDA-approved antidote for acetaminophen overdose; randomized trials leave most over-the-counter capsule wellness claims weakly supported or null.
Methylene Blue (Oral) — The Real Drug, the Small Cognitive Signal, and the Serotonin Syndrome Warning No One Mentions
Methylene blue for oral use is a real drug, not a benign supplement. One small acute imaging study (Rodriguez 2016, n=26, 2 mg/kg) drives the cognitive claim. The Alzheimer's tau story is about a different molecule (LMTX). Serotonin syndrome risk with SSRIs, SNRIs, MAOIs is FDA-warned.
Boron — The Trace Mineral, the Small Study, and What It Actually Earns in a Men's Stack
Boron for men's health — the entire optimization case rests on one small pre-post study in eight men (Naghii 2011). No proper RCT replication exists. Safety margin at 3–10 mg/day is generous (adult UL 20 mg/day). Defensible as a low-cost hedge; not a testosterone move.
Full-Body MRI Screening — Prenuvo, Ezra, Q Bio, and the Incidentaloma Problem
Per 1,000 asymptomatic adults screened with WB-MRI: ~950 abnormal findings, ~15-20 cancers, ~30% trigger workup. Zero RCT mortality evidence. ACR does not recommend for average-risk adults. Vanguard's read on Prenuvo, Ezra, Q Bio.
Galleri — The Multi-Cancer Early Detection Blood Test, and What the 2026 Data Actually Shows
The NHS-Galleri trial missed its primary endpoint at ASCO 2026. High specificity (~99.6%) and PPV (52-62%), modest sensitivity (~30-40% all cancers), zero mortality data. $949 cash pay. No FDA approval as screening. Vanguard's read on the largest multi-cancer detection trial to date.